

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

东曜药业

TOT BIOPHARM International Company Limited

東曜藥業股份有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1875)

**APPOINTMENT OF VICE CHAIRMAN OF THE BOARD AND
CHIEF EXECUTIVE OFFICER AND CHANGE OF AUTHORISED
REPRESENTATIVE**

The Board announces that the following changes have taken effect from 15 October 2020: (i) Ms. Yeh-Huang, Chun-Ying has been appointed as the vice chairman of the Board while she has resigned as the general manager of the Company; (ii) Dr. Liu, Jun has been appointed as the chief executive officer of the Group while he has resigned as the chief operating officer and vice general manager of the Company; and (iii) Ms. Yeh-Huang, Chun-Ying has ceased to be an Authorised Representative of the Company and Dr. Liu, Jun has been appointed as an Authorised Representative of the Company.

APPOINTMENT OF VICE CHAIRMAN OF THE BOARD

The board of directors (the “**Board**”) of TOT BIOPHARM International Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Ms. Yeh-Huang, Chun-Ying (“**Ms. Yeh-Huang**”) has been appointed as the vice chairman of the Board while she has resigned as the general manager of the Company with effect from 15 October 2020. Ms. Yeh-Huang will continue to act as an executive director of the Company to support and promote the strategy formulation and development of the Group.

Ms. Yeh-Huang has confirmed that, as at the date of this announcement, she has no disagreement with the Board, and there are no other matters in relation to her resignation as the general manager of the Company that need to be brought to the attention of the shareholders of the Company.

APPOINTMENT OF CHIEF EXECUTIVE OFFICER

The Board also announces that Dr. Liu, Jun (“**Dr. Liu**”) has been appointed as the chief executive officer of the Group while he has resigned as the chief operating officer and vice general manager of the Company with effect from 15 October 2020. Dr. Liu will continue to act as an executive director and the chief scientific officer of the Company.

Dr. Liu has in-depth scientific research knowledge and managerial experience in the pharmaceutical industry. The Board believes that Dr. Liu's vast experience in the international biological drugs industry will help the Group in achieving its strategic goals and sustainable development.

Dr. Liu has confirmed that, as at the date of this announcement, he has no disagreement with the Board, and there are no other matters in relation to his resignation as the chief operating officer and vice general manager of the Company that need to be brought to the attention of the shareholders of the Company.

CHANGE OF AUTHORISED REPRESENTATIVE

The Board further announces that Ms. Yeh-Huang has ceased to be an authorised representative of the Company under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") (an "**Authorised Representative**") and Dr. Liu has been appointed as an Authorised Representative of the Company with effect from 15 October 2020.

BIOGRAPHICAL DETAILS OF MS. YEH-HUANG

Ms. Yeh-Huang, aged 61, joined the Group on 5 July 2010 as the general manager, and was appointed as an executive director of the Company on 19 January 2016. She is also a member of the Strategy Committee of the Company. Ms. Yeh-Huang has over 30 years of managerial experience in the pharmaceutical industry with a continuous focus on the anti-tumour field, thereby possessing solid ability in industry value chain integration. She obtained a bachelor's degree in pharmacy from Taipei Medical College (now known as Taipei Medical University) in Taiwan in June 1982 and obtained her Taiwan license of pharmacist in June 1983.

As at the date of this announcement, Ms. Yeh-Huang does not have any relationship with any director, senior management, substantial shareholder or controlling shareholder (as defined in the Listing Rules) of the Company. Ms. Yeh-Huang has not held any other directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

As at the date of this announcement, Ms. Yeh-Huang's terms of service with the Company continues to be governed by her existing service contract with the Company. As a director of the Company, she is subject to retirement by rotation at least once every three years and will be eligible for re-election at the annual general meetings of the Company in accordance with the articles of association of the Company.

The remuneration package of Ms. Yeh-Huang remains unchanged for the time being. Please refer to page 44 of the 2020 interim report of the Company published on 21 September 2020 for details. The remuneration package entitled by Ms. Yeh-Huang will be subject to review by the Remuneration Committee of the Company with reference to her responsibilities, contribution, time commitment and prevailing market conditions from time to time.

As at the date of this announcement, Ms. Yeh-Huang has personal interests in 7,115,700 shares of the Company (“**Shares**”) and share options granted under the pre-IPO share option scheme adopted by the Company on 20 February 2013 and subsequently amended on 11 December 2017, 20 December 2018, 12 March 2019, 16 April 2019 and 22 July 2019 (the “**Pre-IPO Share Option Scheme**”) to subscribe for 1,162,500 Shares. Besides, Ms. Yeh-Huang will be interested in 2,897,383 Shares as a grantee under the restricted share award scheme adopted by the Company on 29 May 2020 and subsequently amended on 29 July 2020 (the “**Restricted Share Award Scheme**”) upon the allotment and issue of such Shares to the relevant trustee.

Save as disclosed above, Ms. Yeh-Huang does not have, and is not deemed to have, any interests in any Shares or underlying Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, Ms. Yeh-Huang has confirmed that there is no other information required to be brought to the attention of the shareholders of the Company pursuant to Rule 13.51(2) of the Listing Rules in relation to her appointment as vice chairman of the Board.

BIOGRAPHICAL DETAILS OF DR. LIU

Dr. Liu, aged 53, joined the Group on 17 October 2016 as a vice general manager, and was appointed as an executive director, the chief scientific officer and the chief operating officer of the Company on 26 October 2018, 12 March 2019 and 21 April 2020, respectively. He is also a member of the Strategy Committee of the Company. He is responsible for the research and development, operations management and business development of the Group.

Prior to joining the Group, Dr. Liu was the executive director of biologics research and development department in Shanghai ChemPartner Co., Ltd. between July 2010 and October 2016. Prior to that, he was employed by Bayer US LLC between April 2005 and July 2010 working with Bayer Healthcare as a senior scientist in the United States.

Dr. Liu obtained a Ph.D. in bioanalytical chemistry from the University of California, Davis in the United States in December 2002 and a bachelor’s degree in chemistry from the University of Science & Technology of China in Hefei, Anhui Province, China in July 1991.

As at the date of this announcement, Dr. Liu does not have any relationship with any director, senior management, substantial shareholder or controlling shareholder (as defined in the Listing Rules) of the Company. Dr. Liu has not held any other directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

As at the date of this announcement, Dr. Liu’s terms of service with the Company continues to be governed by his existing service contract with the Company. As a director of the Company, he is subject to retirement by rotation at least once every three years and will be eligible for re-election at the annual general meetings of the Company in accordance with the articles of association of the Company.

The remuneration package of Dr. Liu remains unchanged for the time being. Please refer to page 44 of the 2020 interim report of the Company published on 21 September 2020 for details. The remuneration package entitled by Dr. Liu will be subject to review by the Remuneration Committee of the Company with reference to his responsibilities, contribution, time commitment and prevailing market conditions from time to time.

As at the date of this announcement, Dr. Liu has personal interests in the share options granted under the Pre-IPO Share Option Scheme to subscribe for 1,100,000 Shares. Besides, Dr. Liu will be interested in 2,741,609 Shares as a grantee under the Restricted Share Award Scheme upon the allotment and issue of such Shares to the relevant trustee.

Save as disclosed above, Dr. Liu does not have, and is not deemed to have, any interests in any Shares or underlying Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, Dr. Liu has confirmed that there is no other information required to be brought to the attention of the shareholders of the Company pursuant to Rule 13.51(2) of the Listing Rules in relation to his appointment as chief executive officer of the Group.

By Order of the Board
TOT BIOPHARM International Company Limited
Fu, Shan
Chairman

Hong Kong, 15 October 2020

As at the date of this announcement, the executive directors of the Company are Ms. Yeh-Huang, Chun-Ying and Dr. Liu, Jun; the non-executive directors of the Company are Mr. Fu, Shan, Dr. Kung, Frank Fang-Chien, Mr. Kang, Pei and Mr. Qiu, Yu Min; and the independent non-executive directors of the Company are Ms. Hu, Lan, Dr. Sun, Lijun Richard and Mr. Chang, Hong-Jen.